The second annual meeting of the Horizon MISTRAL project has been held recently in Barcelona, at the Palau Macaya. Our experts, Chris Mann and Laura Mendieta took part in the consortium meeting, where a project follow-up and and update on all working packages was successfully carried out.
At Asphalion we are the regulatory partners of the “Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination” (MISTRAL) project. Coordinated by IrsiCaixa, the project is being carried out in collaboration with ten other institutions from Spain, Denmark, the USA and Sweden, bringing together a team of world-class HIV and microbiome researchers and SMEs.
With a budget of ten million euros, the scientists are analysing the role of the intestinal microbiome in HIV infection with the objective of designing treatments to prevent HIV infection, reinforce the immune system, control the progression of the infection and improve the response to potential vaccinations against the virus.
For more details, you can check the project´s website:
For further information, you can contact us at: info@asphalion.com
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847943
